Villere ST Denis J & Co. LLC Sells 1,607 Shares of Stryker Corporation $SYK

Villere ST Denis J & Co. LLC cut its stake in shares of Stryker Corporation (NYSE:SYK) by 2.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 62,862 shares of the medical technology company’s stock after selling 1,607 shares during the quarter. Stryker makes up 1.8% of Villere ST Denis J & Co. LLC’s holdings, making the stock its 22nd biggest holding. Villere ST Denis J & Co. LLC’s holdings in Stryker were worth $17,312,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AlphaCore Capital LLC grew its holdings in shares of Stryker by 8.7% during the 3rd quarter. AlphaCore Capital LLC now owns 3,879 shares of the medical technology company’s stock worth $1,068,000 after purchasing an additional 311 shares during the period. Running Oak Capital LLC raised its holdings in Stryker by 3.7% in the third quarter. Running Oak Capital LLC now owns 35,955 shares of the medical technology company’s stock valued at $9,913,000 after buying an additional 1,291 shares during the period. Retirement Systems of Alabama raised its holdings in Stryker by 1.0% in the third quarter. Retirement Systems of Alabama now owns 73,200 shares of the medical technology company’s stock valued at $20,159,000 after buying an additional 718 shares during the period. Midwest Capital Advisors LLC raised its stake in shares of Stryker by 27.9% in the 3rd quarter. Midwest Capital Advisors LLC now owns 1,345 shares of the medical technology company’s stock valued at $371,000 after acquiring an additional 293 shares during the period. Finally, Fulcrum Asset Management LLP purchased a new position in Stryker in the third quarter valued at about $737,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the topic of a number of recent research reports. Sanford C. Bernstein restated a “market perform” rating on shares of Stryker in a research note on Wednesday, October 7th. Evercore increased their target price on Stryker from $335.00 to $355.00 in a research note on Wednesday, October 28th. Barclays dropped their target price on Stryker from $375.00 to $365.00 and set an “overweight” rating on the stock in a report on Friday, October 30th. Stifel Nicolaus reduced their target price on shares of Stryker from $330.00 to $325.00 and set a “buy” rating on the stock in a research report on Monday, November 2nd. Finally, Canaccord Genuity Group lowered shares of Stryker from a “buy” rating to a “hold” rating and lowered their price target for the company from $385.00 to $300.00 in a report on Friday, October 30th. Twenty-one research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $342.19.

Insider Transactions at Stryker

In related news, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda Stryker sold 550,000 shares of Stryker stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $325.32, for a total value of $178,926,000.00. Following the completion of the transaction, the director owned 1,701,375 shares of the company’s stock, valued at approximately $553,491,315. The trade was a 24.43% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 901,267 shares of company stock valued at $297,123,701. Insiders own 4.60% of the company’s stock.

Stryker Stock Down 0.1%

Shares of NYSE SYK opened at $325.69 on Tuesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $389.33. The stock’s 50-day simple moving average is $292.26 and its 200-day simple moving average is $323.41. The firm has a market cap of $123.99 billion, a price-to-earnings ratio of 34.69, a PEG ratio of 2.33 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The business had revenue of $6.52 billion during the quarter, compared to analysts’ expectations of $6.62 billion. During the same period in the prior year, the company posted $3.19 EPS. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. As a group, equities analysts anticipate that Stryker Corporation will post 14.84 earnings per share for the current fiscal year.

About Stryker

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings.

The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Founded in 1941 by orthopedic surgeon Dr.